Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges.
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN)
fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS, and EBITDA guidance due to weaker trends in its pharmacogenomics and hereditary cancer testing (women's health) businesses. On the other hand, MYGN significantly beat analysts' EPS and EBITDA expectations. Overall, this was a softer quarter.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 10.9%. This drawdown was worse than the S&P 500’s 5.7% decline.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
